Multiple sclerosis:
Indications for: EXTAVIA
Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Adult Dosage:
Pre-medicate with analgesics and/or antipyretics on treatment days to ameliorate flu-like symptoms. Rotate inj sites. ≥18yrs: initially 0.0625mg SC every other day; increase by 25% every 2 weeks to target dose of 0.25mg SC every other day.
Children Dosage:
<18yrs: not established.
EXTAVIA Warnings/Precautions:
Monitor for hepatic injury; consider discontinuing if elevated transaminase levels or jaundice occurs. Depression. Suicidal ideation. Pre-existing CHF: monitor for worsening cardiac function at initiation and during treatment. Myelosuppression. Discontinue if thrombotic microangiopathy or signs/symptoms of drug-induced lupus erythematosus occurs. Monitor CBCs, differential, platelets, chemistries, liver function tests (at 1, 3, and 6 months then periodically). Latex allergy (diluent). Pregnancy. Nursing mothers.
EXTAVIA Classification:
Immunomodulator.
EXTAVIA Interactions:
Risk of hepatic injury with concomitant hepatotoxic drugs or other products (eg, alcohol).
Adverse Reactions:
Inj site reactions (necrosis, cellulitis, abscess, inflammation, pain), lymphopenia, flu-like symptoms, myalgia, leukopenia, neutropenia, increased liver enzymes, headache, hypertonia, rash, insomnia, abdominal pain, asthenia; rare: hepatic injury, anaphylaxis (discontinue if occurs), possible seizures.
Generic Drug Availability:
NO
How Supplied:
Single-use vials—15 (w. prefilled diluent syringe, supplies)
